Hank Payments
Source: Hank Payments.
  • Hank Payments has closed its non-brokered private placement of debenture units for gross proceeds of $800,000
  • The company issued 800 convertible debenture units priced at $1,000
  • Each debenture consists of one convertible debenture and 3,333 common share purchase warrants
  • The debentures mature on June 13, 2025, and bear interest of 10 per cent per annum
  • The company has announced a new private placement for up to $1,000,000 under the same terms as the previous convertible debenture placement
  • Hank is a Fintech software-as-a-service (SaaS) company that supports consumer budgeting and cash management automation
  • Hank Payments Corp. (HANK) opened trading at C$0.10

Hank Payments Corp. (HANK) has closed its previously announced non-brokered private placement for gross proceeds of $800,000

The company issued 800 convertible debenture units priced at $1,000. Each debenture consists of one convertible debenture and 3,333 common share purchase warrants. The debentures mature on and become payable 36 months from the closing date and bear interest at a fixed rate of 10 per cent per annum, payable quarterly.

The company has announced a new private placement for up to $1,000,000 under the same terms as the previous convertible debenture placement.

Hank is a Fintech software-as-a-service (SaaS) company that supports consumer budgeting and cash management automation.

Hank Payments Corp. (HANK) opened trading at C$0.10.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.